- Home
- JWSM vs AGEN Comparison
JWSM vs AGEN Comparison
Compare JWSM & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWSM
- AGEN
- Stock Information
- Founded
- JWSM 2020
- AGEN 1994
- Country
- JWSM United States
- AGEN United States
- Employees
- JWSM N/A
- AGEN N/A
- Industry
- JWSM Blank Checks
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JWSM Finance
- AGEN Health Care
- Exchange
- JWSM Nasdaq
- AGEN Nasdaq
- Market Cap
- JWSM 308.5M
- AGEN 97.7M
- IPO Year
- JWSM 2021
- AGEN 2000
- Fundamental
- Price
- JWSM $11.31
- AGEN $4.49
- Analyst Decision
- JWSM
- AGEN Buy
- Analyst Count
- JWSM 0
- AGEN 3
- Target Price
- JWSM N/A
- AGEN $10.00
- AVG Volume (30 Days)
- JWSM 2.7K
- AGEN 339.2K
- Earning Date
- JWSM 01-01-0001
- AGEN 11-05-2024
- Dividend Yield
- JWSM N/A
- AGEN N/A
- EPS Growth
- JWSM N/A
- AGEN N/A
- EPS
- JWSM N/A
- AGEN N/A
- Revenue
- JWSM N/A
- AGEN $159,630,000.00
- Revenue This Year
- JWSM N/A
- AGEN N/A
- Revenue Next Year
- JWSM N/A
- AGEN $0.04
- P/E Ratio
- JWSM N/A
- AGEN N/A
- Revenue Growth
- JWSM N/A
- AGEN 60.67
- 52 Week Low
- JWSM $10.50
- AGEN $4.18
- 52 Week High
- JWSM $11.32
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- JWSM 91.47
- AGEN 40.14
- Support Level
- JWSM $11.14
- AGEN $4.50
- Resistance Level
- JWSM $11.32
- AGEN $4.78
- Average True Range (ATR)
- JWSM 0.00
- AGEN 0.28
- MACD
- JWSM -0.00
- AGEN 0.02
- Stochastic Oscillator
- JWSM 50.00
- AGEN 42.47
About JWSM Jaws Mustang Acquisition Corp.
Jaws Mustang Acquisition Corp is a blank check company. it is formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).